Aligos Therapeutics (ALGS) Other financing activities (2019 - 2025)

Aligos Therapeutics (ALGS) has reported Other financing activities for 7 consecutive years, with $124000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Other financing activities fell 10.79% year-over-year to $124000.0; the trailing twelve-month figure through Dec 2025 stood at $263000.0 (up 14.85% YoY), and the FY2025 full-year result was $304000.0, down 30.28% from the prior year.
• Other financing activities slipped to $124000.0 in Q4 2025 per ALGS's latest filing, from $139000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $438000.0 in Q2 2023 and bottomed at $10000.0 in Q1 2022.
• Historically, Other financing activities has averaged $122363.6 across 5 years, with a median of $96000.0 in 2021.
• The sharpest annual moves came in 2022 and 2023: Other financing activities plunged 89.58% in 2022, then surged 333.66% in 2023.
• Over 5 years, Other financing activities stood at $18000.0 in 2021, then soared by 422.22% to $94000.0 in 2022, then declined by 4.26% to $90000.0 in 2023, then surged by 54.44% to $139000.0 in 2024, then fell by 10.79% to $124000.0 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $124000.0, $139000.0, and $90000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.